science wire

University of Queensland scientists are heading 'stateside' with the support of 2020 Fulbright scholarships.

Novel combination regimen includes first-in-class antibody-drug conjugate that specifically targets CD79b Targeted off-the-shelf treatment provides much-needed new option for people with relapsed or

Patients & Caregivers Healthcare Professionals Society & ESG Mayzent (siponimod) is the first and only oral treatment specifically indicated for patients with secondary progressive multiple s

Not enough focus is being paid to using antibiotics more appropriately to minimise the threat of drug-resistant bugs, said an expert in a recent talk. Alison Holmes, Professor of Infectious Diseases at Imperial College London and Director of Infection Prevention and Control at Imperial College Healthcare NHS Trust, is leading a newly created centre to tackle drug-resistant infections.

In a UCLA-led study, children and adolescents with a high risk for developing bipolar disorder stayed healthier for longer periods when their family members participated in their psychotherapy sessions.

The threat posed by drug resistant infections should be taken as seriously as climate change, says an Imperial expert.

Genetic modification of babies in China one year ago was universally condemned. At the same time, CRISPR treatments are on their way into our clinics.

Up to 30,000 lives could be saved over the next decade thanks to a proposed pioneering government collaboration with pharmaceutical company Novartis to tackle heart disease - a leading cause of death in the UK.

The University of Michigan and Sun Pharma Advanced Research Company have launched a partnership to accelerate the development of potential new medicines for a wide range of diseases. The new venture will provide up to a total of $10 million in financial support and in-kind industry resources to move various promising drug-discovery research projects within the university toward the ultimate goal of new therapies for patients.

The NHS should raise their five-year lung cancer survival targets to 35% by 2030, concludes a new 'state of the nation' policy report conducted by UCL.

The trial, funded by a £2.1 million grant from the National Institute for Health Research (NIHR) , will test whether a commonly prescribed dementia drug could prevent debilitating falls for people with the disease.

For Cambridge students For our researchers Business and enterprise Colleges and Departments Email and phone search Give to Cambridge Museums and collections Undergraduate Events and open days Fees an

Swiss researchers, including UNIGE, show that 50% of transplant recipients develop severe infections within a year of the operation, which can lead to death.

Patients & Caregivers Healthcare Professionals Society & ESG Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly hig

A new study suggests that China needs a national strategy to improve hospital care for heart patients. The study, a collaboration among researchers in China and the United States, appears Jan. 8 in the journal JAMA Network Open. Harlan Krumholz, M.D., cardiologist and director of the Yale Center for Outcomes Research and Evaluation (CORE), is co-senior author of the study along with Chinese researcher Jing Li, M.D. The Chinese government has made heart patient care a priority in the past decade, initiating extensive health care reforms.

Leftover prescription opioids pose big risks to kids, yet most parents keep their own and their child's unused painkillers even after they're no longer medically necessary for pain.

The King Abdullah International Medical Research Centre (KAIMRC), in collaboration with the University of Oxford's Jenner Institute has started a Phase I clinical trial in the Kingdom of Saudi Arabia (KSA) for a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

Patients at high risk for diabetes are also at a high risk for heart disease - but not because of higher sugar levels, according to new research led by the University of Glasgow.

Patients & Caregivers Healthcare Professionals Society & ESG Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication   Fevipipra

All antitrust approvals required to close the transaction received. Roche and Spark Therapeutics, Inc.

Patients & Caregivers Healthcare Professionals Society & ESG In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one 1  

Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).

This week Graphene@Manchester hosted a jam-packed two-day (10-11 December) event showcasing the hottest topics in the field of graphene.

Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study s

Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results

Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurr

Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.

Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more

Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di

In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia

Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu

ç €äoe“äž­æ–‡ à€¹à€¿à€šà¥à€Šà¥€ Português Español Share on: Share on Twitter Share on Facebook Share on LinkedIn When 14-year-old Daniel Liu buttons his lab coat and goes to work, he transforms from a teenager into a fearless and persistent researcher.

Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Roche today anno

Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation   Data for MBG453, an innovative anti-TIM

Every year, 1.5 million people die from tuberculosis (TB) worldwide. Diagnosis and treatment is particularly difficult in remote rural areas.

Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with baseline immunosuppressant therapy Satralizumab targets the interleukin-6 (IL-6) receptor, a potential key driver of neuromyelitis optica spectrum disorder (NMOSD) NMOSD is a rare, debilitating autoimmune disease of the central nervous system that can cause visual impairment, motor disability and even death Roche

New University of Birmingham research funded by the British Heart Foundation could improve treatments for a potentially deadly condition that affects tens of thousands of people in the UK each year.